Wildiers Hans, de Glas Nienke A
Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
Lancet Healthy Longev. 2020 Oct;1(1):e43-e47. doi: 10.1016/S2666-7568(20)30001-5.
Studies on new anticancer drugs often inappropriately conclude that these treatments are well tolerated and feasible in the older population with cancer, despite the drug being investigated in only a selection of healthy older patients who are not representative of the true older population. In this Personal View we outline examples of reports that provide misleading information to clinicians, mostly because the tolerance and efficacy were not assessed according to frailty status and only a few people who are frail were included. We also provide solutions on how to inform clinicians, patients, and health authorities more clearly about the benefits and disadvantages of new and upcoming anticancer drugs for older people with cancer.
关于新型抗癌药物的研究常常得出不恰当的结论，即这些治疗方法在老年癌症患者中耐受性良好且可行，尽管所研究的药物仅在一部分健康老年患者中进行了试验，而这些患者并不能代表真正的老年人群体。在这篇个人观点文章中，我们概述了一些向临床医生提供误导性信息的报告实例，主要原因是未根据虚弱状态评估耐受性和疗效，且纳入的虚弱患者人数很少。我们还提供了一些解决方案，说明如何更清晰地向临床医生、患者和卫生当局告知新型及即将上市的抗癌药物对老年癌症患者的利弊。
